
Episode 78: Dr. Kristin Gleitsman on Using AI to Make Better Drug Development Decisions
22 окт 2026 · 42:55
Естественные наукиОписание
After years of building discovery engines inside diagnostics, Kristin Gleitsman has become one of the more skeptical voices in AI and biology. A Caltech chemistry PhD, Kristin built Veracyte’s Discovery Research function from the ground up and helped shape the strategy behind its acquisition of C2i Genomics. Now, as Chief Science Officer of Eigen Bio, the focus is on a harder question than building bigger models: what has an AI model actually earned the right to claim?
In this episode, Kristin unpacks why more data layers don’t automatically mean more biological truth, how better mechanistic evidence could change drug development decisions, and what it takes to hold AI-bio claims, including your own company’s, to a higher standard. Kristin also shares lessons from the weekly AI∩Bio newsletter on separating real progress from hype.
Check out Eigen Bio: https://eigenbioai.com/
Read AI∩Bio: Reading the Revolution: https://kristinrulegleitsman.com/ai-∩-bio/
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#PetriDishPerspectives #AIinBiotech #DrugDiscovery #PrecisionMedicine #Diagnostics #Multiomics #Biotech #HealthTech #Oncology #AIBio #EigenBio
© 2026 The Perspective Bureau LLC. All rights reserved.
Комментарии
Комментариев пока нет — напишите первый.